Treatment for Alzheimer’s

About

Alzheimer’s disease (AD) is considered an emerging epidemic for which there is currently no cure. It is notably the most prevalent form of dementia afflicting the elderly and is associated with a multitude of genetic, environmental, epigenetic, dietary and lifestyle risk factors. Clinical trials involving various potential therapeutic drugs have failed; largely due to adverse side-effects. There is therefore a need for compounds which, in use, modulate the production and levels of the precursor proteins which cause the undesired aggregation of the proteins which result in AD. Due to the minimal understanding of the disease causing mechanism, currently only palliative treat-ment options for AD are available. The proposed solution is a new compound for the treatment of Alzheimer’s disease. Once administered, this compound prevents the aggregation of proteins whose agglomeration is linked to the development and progression of AD. The developed compound specifically treats the neuronal loss characteristics of the disease. The developed solution also includes a method of modulating the levels of AD-relevant proteins, effectively resulting in the prevention or treatment of the dis-ease. The proposed compound has been successfully tested in mice; with results showing an im-provement in memory, and decreased formation of plaques (agglomerated proteins) associated with progression of AD.